Merck and NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.
Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products.
The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics.
Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends